On a recent podcast, the Secretary of Health and Human Services Robert F. Kennedy Jr. started talking about peptides as if they were part of the next wave of medicine. Sitting across from Joe Rogan, he described using them himself and suggested that compounds previously restricted by the Food and Drug Administration might soon become available again through compounding pharmacies.
Within hours, the clips were everywhere: Access to peptides was being restored. It sounded as though something meaningful had shifted, as if a door that'd been unnecessarily closed was now open. But what most people heard and what was actually communicated aren't one and the same.
If you’ve been hearing more about peptides lately, you’re not imagining that. But peptides aren't a new technology: They're short chains of amino acids, the same basic building blocks that make up proteins throughout the body. In everyday biology, they act as messengers, helping regulate processes like metabolism, inflammation, and tissue repair. Medicine has relied on them for decades. Insulin, for example, is a peptide, and the GLP-1 medications that have reshaped treatment for diabetes and weight loss are peptides as well.
That familiarity can be misleading.
The word peptide has started to function as a kind of umbrella, suggesting that anything in this category carries the same credibility. In reality, each peptide is its own molecule, each of which behaves differently in the body, and each requires its own evidence of efficacy. The fact that one peptide has transformed modern medicine tells us nothing about whether another one will.
What has changed is not the science, but the way these compounds are being discussed.
You’ll hear names like BPC-157, CJC-1295, MOTS-C, and Ipamorelin. Even saying them out loud, they sound precise, well engineered, and like something that must have been carefully studied.
That’s part of the appeal. When something sounds scientific, we tend to feel a sense of security around it — as if the language itself is proof that someone has done the work. But language can create confidence before the evidence actually exists.
That matters, because many of the peptides currently being promoted in clinics and across social media are still early in their scientific "story." Much of the research behind them comes from animal studies or small experimental trials — not the kind of large, carefully controlled human studies that define modern medical evidence.
Historically, fewer than 10 percent of treatments that show promise in animal models ultimately prove to be safe and effective in humans. That doesn’t mean these compounds will never have a role in medicine, but we don’t yet have the evidence to say for certain whether they work.
In the meantime, what fills that vacuum of uncertainty are stories: Someone’s injury healed faster. Someone slept better. Someone felt more like themselves again. These accounts are often sincere and compelling, and they spread quickly in the same spaces where the science is being discussed.
But in medicine, we’ve learned that individual experiences can be misleading. The body changes over time, and symptoms improve on their own. Plus, expectations shape what we notice and how we interpret it. A story can feel like proof, but it's not the same thing.
There's also another layer most patients never see: Many of the peptides currently circulating through wellness clinics aren’t FDA-approved medications. Some are prepared through compounding pharmacies, which operate under a different set of regulatory standards than pharmaceutical manufacturers. Others are sourced through suppliers that label their products "for research use only," a designation that allows them to exist outside the framework designed for drugs intended for patients.
By the time a compound reaches someone, that distinction has often disappeared. What remains is the setting, the language, and the assumption that what’s being offered has already passed through the safeguards we associate with modern medicine.
Often, it has not.
This moment is particularly relevant for women in midlife, who are increasingly being targeted with messaging around metabolism, energy, recovery, and longevity. For many, that attention lands in a space where traditional medical care hasn’t always provided clear or satisfying answers, and the desire for something that works is not only understandable, it’s deeply human.
I would love a therapy that improves sleep, supports metabolism, helps the body recover, and eases the transition of midlife without side effects. We all would. But the absence of a long list of side effects isn't always a sign that a treatment is safer. Often, it’s a sign that a treatment has not been studied long enough to reveal them.
That's the quieter reality behind the current enthusiasm for peptides. Some are powerful, well-studied tools that have transformed care. Many others are still experimental, moving through a space where regulatory language, scientific possibility, and marketing narratives overlap in ways that can be difficult to interpret.
The question isn’t whether peptides are good or bad: It’s whether what’s being offered has actually been proven to work and proven to be safe. And in medicine, those answers take time.
Sarah Berg, MD, is a board-certified OB-GYN and certified menopause practitioner who spent over a decade in clinical practice caring for women across all stages of life. She now focuses on evidence-based education and storytelling that helps women understand their bodies, prioritize preventative care, and navigate midlife health with clarity and confidence. Learn more at Selfority.
